Is Allergen Immunotherapy in Children Disease Modifying? A Review of the Evidence
Purpose of Review
Although evidence supports a beneficial effect of allergen immunotherapy on the symptoms of allergic respiratory disease and food allergy, it is not clear whether immunotherapy modifies the natural history of these conditions.
In aeroallergen immunotherapy, studies suggest that prevention of asthma can be attained. Less evident is the ability of immunotherapy to prevent new allergen sensitizations and more studies are needed to test whether immunotherapy can continue suppressing airway symptoms after treatment discontinuation. In food allergen immunotherapy, there is evidence that unresponsiveness to a food challenge can be sustained in some treatment recipients, but little knowledge exists as to the dose and duration of treatment that can optimize this effect.
Suggestive evidence exists that allergen immunotherapy can modify allergic disease in children, but definitive studies are lacking. More research in the field is required.
KeywordsAeroallergen immunotherapy Food allergen immunotherapy Desensitization Sustained unresponsiveness Asthma prevention
Compliance with Ethical Standards
Conflict of Interest
Dr. Togias is Chief of the NIAID/DAIT Branch that has funded several of the studies cited in this review. The other authors declare no conflicts of interest relevant to this manuscript.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 5.Jackson DJ, Evans MD, Gangnon RE, Tisler CJ, Pappas TE, Lee WM, et al. Evidence for a causal relationship between allergic sensitization and rhinovirus wheezing in early life. Am J Respir Crit Care Med. 2012;185(3):281–5. https://doi.org/10.1164/rccm.201104-0660OC.CrossRefPubMedPubMedCentralGoogle Scholar
- 9.Murray CS, Woodcock A, Langley SJ, Morris J, Custovic A, Is t. Secondary prevention of asthma by the use of inhaled fluticasone propionate in wheezy INfants (IFWIN): double-blind, randomised, controlled study. Lancet. 2006;368(9537):754–62. https://doi.org/10.1016/S0140-6736(06)69285-4.CrossRefPubMedGoogle Scholar
- 16.Lim JH, Kim JY, Han DH, Lee CH, Hong SN, Wee JH, et al. Sublingual immunotherapy (SLIT) for house dust mites does not prevent new allergen sensitization and bronchial hyper-responsiveness in allergic rhinitis children. PLoS One. 2017;12(8):e0182295. https://doi.org/10.1371/journal.pone.0182295.CrossRefPubMedPubMedCentralGoogle Scholar
- 21.Jacobsen L, Niggemann B, Dreborg S, Ferdousi HA, Halken S, Host A, et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy. 2007;62(8):943–8. https://doi.org/10.1111/j.1398-9995.2007.01451.x.CrossRefPubMedGoogle Scholar
- 22.Novembre E, Galli E, Landi F, Caffarelli C, Pifferi M, De Marco E, et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2004;114(4):851–7. https://doi.org/10.1016/j.jaci.2004.07.012.CrossRefPubMedGoogle Scholar
- 23.•• Valovirta E, Petersen TH, Piotrowska T, Laursen MK, Andersen JS, Sorensen HF, et al. Results from the 5-year SQ grass sublingual immunotherapy tablet asthma prevention (GAP) trial in children with grass pollen allergy. J Allergy Clin Immunol. 2018;141(2):529–38 e13. https://doi.org/10.1016/j.jaci.2017.06.014. Children randomized to grass SLIT or placebo for 3 years and followed for 2-years after the completion of therapy. Starting in year 2 and through the final 5 th year, SLIT-treated participants were significantly less likely to be using asthma medications or experiencing asthma symptoms than those who received Placebo. CrossRefPubMedGoogle Scholar
- 26.Lau S, Illi S, Sommerfeld C, Niggemann B, Bergmann R, von Mutius E, et al. Early exposure to house-dust mite and cat allergens and development of childhood asthma: a cohort study. Multicentre Allergy Study Group Lancet. 2000;356(9239):1392–7.Google Scholar
- 28.Durham SR, Emminger W, Kapp A, de Monchy JG, Rak S, Scadding GK, et al. SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol. 2012;129(3):717–725.e5. https://doi.org/10.1016/j.jaci.2011.12.973.CrossRefPubMedGoogle Scholar
- 29.• Scadding GW, Calderon MA, Shamji MH, Eifan AO, Penagos M, Dumitru F, et al. Effect of 2 years of treatment with sublingual grass pollen immunotherapy on nasal response to allergen challenge at 3 years among patients with moderate to severe seasonal allergic rhinitis: the GRASS randomized clinical trial. JAMA. 2017;317(6):615–25. https://doi.org/10.1001/jama.2016.21040. This trial demonstrated that 3 years of AIT with either SLIT or SCIT was insufficent to produce tolerance one year after discontinuation of therapy. CrossRefPubMedPubMedCentralGoogle Scholar
- 35.Scadding GW, Shamji MH, Jacobson MR, Lee DI, Wilson D, Lima MT, et al. Sublingual grass pollen immunotherapy is associated with increases in sublingual Foxp3-expressing cells and elevated allergen-specific immunoglobulin G4, immunoglobulin a and serum inhibitory activity for immunoglobulin E-facilitated allergen binding to B cells. Clin Exp Allergy. 2010;40(4):598–606. https://doi.org/10.1111/j.1365-2222.2010.03462.x.PubMedGoogle Scholar
- 40.Anagnostou K, Islam S, King Y, Foley L, Pasea L, Bond S, et al. Assessing the efficacy of oral immunotherapy for the desensitisation of peanut allergy in children (STOP II): a phase 2 randomised controlled trial. Lancet. 2014;383(9925):1297–304. https://doi.org/10.1016/S0140-6736(13)62301-6.CrossRefPubMedPubMedCentralGoogle Scholar
- 41.Bird JA, Spergel JM, Jones SM, Rachid R, Assa'ad AH, Wang J, et al. Efficacy and safety of AR101 in oral immunotherapy for peanut allergy: results of ARC001, a randomized, double-blind, placebo-controlled phase 2 clinical trial. J Allergy Clin Immunol Pract. 2018;6(2):476–485.e3. https://doi.org/10.1016/j.jaip.2017.09.016.CrossRefPubMedGoogle Scholar
- 42.Skripak JM, Nash SD, Rowley H, Brereton NH, Oh S, Hamilton RG, et al. A randomized, double-blind, placebo-controlled study of milk oral immunotherapy for cow's milk allergy. J Allergy Clin Immunol. 2008;122(6):1154–60. https://doi.org/10.1016/j.jaci.2008.09.030.CrossRefPubMedPubMedCentralGoogle Scholar
- 43.Narisety SD, Frischmeyer-Guerrerio PA, Keet CA, Gorelik M, Schroeder J, Hamilton RG, et al. A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy. J Allergy Clin Immunol. 2015;135(5):1275–1282.e6. https://doi.org/10.1016/j.jaci.2014.11.005.CrossRefPubMedGoogle Scholar
- 44.Sampson HA, Shreffler WG, Yang WH, Sussman GL, Brown-Whitehorn TF, Nadeau KC, et al. Effect of varying doses of epicutaneous immunotherapy vs placebo on reaction to peanut protein exposure among patients with peanut sensitivity: a randomized clinical trial. JAMA. 2017;318(18):1798–809. https://doi.org/10.1001/jama.2017.16591.CrossRefPubMedPubMedCentralGoogle Scholar
- 46.Andorf S, Purington N, Block WM, Long AJ, Tupa D, Brittain E, et al. Anti-IgE treatment with oral immunotherapy in multifood allergic participants: a double-blind, randomised, controlled trial. Lancet Gastroenterol Hepatol. 2018;3(2):85–94. https://doi.org/10.1016/S2468-1253(17)30392-8.CrossRefPubMedGoogle Scholar
- 47.•• Du Toit G, Sayre PH, Roberts G, Sever ML, Lawson K, Bahnson HT, et al. Effect of avoidance on peanut allergy after early peanut consumption. N Engl J Med. 2016;374(15):1435–43. https://doi.org/10.1056/NEJMoa1514209. Follow -on study to the LEAP trial where participants who had been consuming peanuts avoided them between 5 and 6 years of age and maintained their ability to eat them without reaction. CrossRefPubMedGoogle Scholar
- 48.• Jones SM, Burks AW, Keet C, Vickery BP, Scurlock AM, Wood RA, et al. Long-term treatment with egg oral immunotherapy enhances sustained unresponsiveness that persists after cessation of therapy. J Allergy Clin Immunol. 2016;137(4):1117–1127.e10. https://doi.org/10.1016/j.jaci.2015.12.1316. This study suggests that, as with AIT, that a longer duration of FAIT may be more effective for development of sustained unresponsivenss. CrossRefPubMedPubMedCentralGoogle Scholar
- 50.•• Du Toit G, Roberts G, Sayre PH, Bahnson HT, Radulovic S, Santos AF, et al. Randomized trial of peanut consumption in infants at risk for peanut allergy. N Engl J Med. 2015;372(9):803–13. https://doi.org/10.1056/NEJMoa1414850. Landmark study demonstrating that in children at high risk of food allergy due to eczema or egg allergy, early consumption of peanut prevents the develoment of peanut allergy. CrossRefPubMedPubMedCentralGoogle Scholar
- 51.Wright BL, Kulis M, Orgel KA, Burks AW, Dawson P, Henning AK, et al. Component-resolved analysis of IgA, IgE, and IgG4 during egg OIT identifies markers associated with sustained unresponsiveness. Allergy. 2016;71(11):1552–60. https://doi.org/10.1111/all.12895.CrossRefPubMedPubMedCentralGoogle Scholar
- 52.Syed A, Garcia MA, Lyu SC, Bucayu R, Kohli A, Ishida S, et al. Peanut oral immunotherapy results in increased antigen-induced regulatory T-cell function and hypomethylation of forkhead box protein 3 (FOXP3). J Allergy Clin Immunol. 2014;133(2):500–10. https://doi.org/10.1016/j.jaci.2013.12.1037.CrossRefPubMedPubMedCentralGoogle Scholar
- 54.Wambre E, Bajzik V, DeLong JH, O'Brien K, Nguyen QA, Speake C, et al. A phenotypically and functionally distinct human TH2 cell subpopulation is associated with allergic disorders. Sci Transl Med. 2017;9(401):eaam9171. https://doi.org/10.1126/scitranslmed.aam9171.CrossRefPubMedPubMedCentralGoogle Scholar
- 56.Hsiao K-H, Ponsonby A-L, Axelrad C, Pitkin S, Tang MLK. Long-term clinical and immunological effects of probiotic and peanut oral immunotherapy after treatment cessation: 4-year follow-up of a randomised, double-blind, placebo-controlled trial. The Lancet Child & Adolescent Health, 2017;1(2):97–105. https://doi.org/10.1016/S2352-4642(17)30041-X.
- 59.Escudero C, Rodriguez Del Rio P, Sanchez-Garcia S, Perez-Rangel I, Perez-Farinos N, Garcia-Fernandez C, et al. Early sustained unresponsiveness after short-course egg oral immunotherapy: a randomized controlled study in egg-allergic children. Clin Exp Allergy. 2015;45(12):1833–43. https://doi.org/10.1111/cea.12604.CrossRefPubMedGoogle Scholar
- 60.Wood RA, Kim JS, Lindblad R, Nadeau K, Henning AK, Dawson P, et al. A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow’s milk allergy. J Allergy Clin Immunol. 2016;137(4):1103–1110.e11. https://doi.org/10.1016/j.jaci.2015.10.005.CrossRefPubMedGoogle Scholar